RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:90058

Spinal cord injury

high confidenceDisorder

Publications

116,864

99.6th percentile

Trials

1,636

Interventional, condition-specific

Researchers

1,277

Distinct authors in sample

Gene link

—

Readiness

4/6

Stages with a signal

How rare: 1-5 / 10 000 — about one to five people per ten thousand (still uncommon, but less ultra-rare).

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (2)

injury of spinal cord · spinal cord injury

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

4/6 stages with a signal

An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.

  1. Gene identifiedNot found

    No GenCC disease–gene assertion in this build

  2. LiteraturePresent

    116,864 matched papers (69,503 in last 10 years) Source

  3. Phenotype characterisedPresent

    15 HPO annotations (e.g. Spinal cord lesion; Urinary bladder sphincter dysfunction; Paralytic ileus) Source

  4. Animal modelNot found

    No Alliance genotype “model of” associations via Monarch for these Mondo IDs

  5. Orphan designationPartial

    15 EMA designations (none yet with FDA orphan-indication approval) — e.g. autologous human bone marrow-derived haematopoietic and mesenchymal stem cells depleted of erythrocytes, monocytes and lymphocytes Source

  6. Interventional trialPresent

    1,636 matched on ClinicalTrials.gov (405 recruiting in sample)

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Not yet — the cause hasn't been pinned down in GenCC.

No strong gene–disease assertion joined for this Orphanet entity.

Phenotypes (Monarch / HPO)

15

Associated phenotypes · MONDO:0043797

  • Spinal cord lesion
  • Urinary bladder sphincter dysfunction
  • Paralytic ileus
  • Somatic sensory dysfunction
  • Weakness due to upper motor neuron dysfunction

Showing 5 of 15 — open Monarch for the full list.

Animal models (Monarch / Alliance)

None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.

Monarch fetch 2026-07-29

Therapies

Designations, candidates, and chemicals

FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.

Orphan designation (FDA · EMA)

15

Designations · no FDA orphan-indication approval yet

  • EMA autologous human bone marrow-derived haematopoietic and mesenchymal stem cells depleted of erythrocytes, monocytes and lymphocytesTreatment of spinal cord injury · 24/04/2019 · PositiveEMA designation
  • EMA (4Z,7R,8E,10E,12Z,14S,16Z,19Z)-7,14-Dihydroxydocosa-4,8,10,12,16,19-hexaenoic acidTreatment of spinal cord injury · 23/02/2026 · PositiveEMA designation
  • EMA autologous blood-derived tumour and hypoxia educated macrophagesTreatment of spinal cord injury · 22/05/2023 · PositiveEMA designation
  • EMA oremepermin alfaTreatment of spinal cord injury · 20/04/2026 · PositiveEMA designation
  • EMA Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Cys-Asp-Met-Ala-Glu-His-Thr-Glu-Arg-Leu-Lys-Ala-Asn-Asp-Ser-Leu-Lys-Leu-Ser-Gln-Glu-Tyr-Glu-Ser-Ile-NH2Treatment of spinal cord injury · 19/02/2021 · PositiveEMA designation
  • EMA Oxymetazoline hydrochlorideTreatment of spinal cord injury · 17/07/2017 · PositiveEMA designation
  • EMA ElezanumabTreatment of spinal cord injury · 16/05/2022 · PositiveEMA designation
  • EMA autologous adipose-derived stem cellsTreatment of spinal cord injury · 16/04/2024 · PositiveEMA designation

Sources: FDA OOPD · EMA orphan designations

Open Targets candidates

60

Drugs / clinical candidates · MONDO_0043797

CTD chemicals (MyDisease.info)

44 associated chemicals · 242 pathways. Therapeutic evidence is listed first when present — not a treatment recommendation.

  • 2',3'-dialdehyde ATP · therapeutic
  • 4-iodo-2,5-dimethoxyphenylisopropylamine · therapeutic
  • Acetylcarnitine · therapeutic
  • Atorvastatin · therapeutic
  • Baclofen · therapeutic
  • Cannabidiol · therapeutic
  • coomassie Brilliant Blue · therapeutic
  • Cytidine Diphosphate Choline · therapeutic
  • GABA-A Receptor Agonists · therapeutic
  • GABA-B Receptor Agonists · therapeutic
  • geraniol · therapeutic
  • Indomethacin · therapeutic

Pathways: EGFR tyrosine kinase inhibitor resistance; Platinum drug resistance; Base excision repair; MAPK signaling pathway; Ras signaling pathway; Rap1 signaling pathway; Calcium signaling pathway; cGMP-PKG signaling pathway

MyDisease.info · MONDO:0043797

Literature

Is anyone studying this?

116,864

116,864 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.

116,864 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).

69,503 in the last 10 years · high confidence · 99.6th percentile (publications denominator)

Phrase hits: 116,395 · MeSH hits: 1,799

Open Europe PMC search

Who's working on it?

1,277

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.

  1. 01
    Zhang Y6 papers · 2026

    Central Hospital Affiliated to Shandong First Medical University, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, Shandong, China.

    Papers in Europe PMC
  2. 02
    Wang L5 papers · 2026

    The Second Department of Spine Surgery, Yantaishan Hospital, Yantai, People's Republic of China.

    Papers in Europe PMC
  3. 03
    Wang Y5 papers · 2026

    Southeast University, Nanjing, Jiang Su Province, China; Department of Spine Surgery, the Affiliated ZhongDa Hospital of Southeast University, Nanjing, Jiang Su Province, China. Electronic address: wangyttod@163.com.

    Papers in Europe PMC
  4. 04
    Yang Y5 papers · 2026

    National Clinical Research Center of Geriatric Disorders, Xiangya Hospital of Central South University.

    Papers in Europe PMC
  5. 05
    Zhang J5 papers · 2026

    WeiNan Central Hospital, China.

    Papers in Europe PMC
  6. 06
    Cao Y4 papers · 2026

    Department of Orthopedics, Peking University Third Hospital, Beijing, People's Republic of China.

    Papers in Europe PMC
  7. 07
    Chandran G4 papers · 2026

    Department of Medicine, Division of Rehabilitation Medicine, National University Hospital, National University Health System, Singapore, Singapore.

    Papers in Europe PMC
  8. 08
    Liu W4 papers · 2026

    Department of Hematology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, 200120, China.

    Papers in Europe PMC
  9. 09
    Shankar R4 papers · 2026

    Clinical Research & Innovation Office, Tan Tock Seng Hospital, National Healthcare Group, Singapore, Singapore.

    Papers in Europe PMC
  10. 10
    Wang S4 papers · 2026

    Center for Regenerative Nanomedicine, Northwestern University, Chicago, IL, USA.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

1,636

interventional trials for this specific condition

1,636 interventional trials matched this specific condition name; 405 currently recruiting in our sample. 3,631 trials are registered for injury, the broader category — shown separately because they may or may not enrol this specific subtype.

Data as of 11 September 2026

1,636 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 100th percentile).

high confidence · 100th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

1,636 interventional trials matched after quoted-phrase search and title/condition post-filter.

Broader category: injury

3,631

Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.

Worth raising with a clinician. How we count trials.

Recruiting under the broader category

Observational and natural-history studies

331 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.

Recruiting or not-yet-recruiting

Open the complete matched search on ClinicalTrials.gov

Other registries (secondary)

Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.

raw 50 · after dedupe 50 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 50 · dropped 0 · fetched 2026-07-30

Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri

No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).

Uncertain / not reviewed (50)

Where to find support

Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.

Orphanet entry for Spinal cord injury — check Associations / patient organisations on that page.

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Spinal cord injury" OR "injury of spinal cord" OR "injury of the spinal cord"

Run this search on Europe PMC

MeSH descriptor terms unioned into the query: Spinal Cord Injuries

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Spinal cord injury" OR "injury of spinal cord" OR "injury of the spinal cord" OR "Spinal Cord Injuries"

Interventional trials matched via: both, phrase, mesh (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).

Study-type breakdown: 1636 interventional · 331 observational · 3 expanded access. Only interventional studies enter the trial headline.

Parent-category trials query:

"injury"

Query health: ok — strategies attempted: phrase, mesh; with hits: phrase, mesh

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus

Ingested 2026-07-27T03:35:56.910Z